Monopar Therapeutics
Stock Forecast, Prediction & Price Target
Monopar Therapeutics (MNPR) stock Price Target by analysts
$29.5
Potential downside: -11.96%
Monopar Therapeutics price prediction
What is Monopar Therapeutics stock analysts` prediction?
Monopar Therapeutics stock forecast: Based on 2 Wall Street analysts` predicted price targets for Monopar Therapeutics in the last 3 months, the avarage price target is $29.5, with a high forecast of $NaN. The average price target represents a -11.96% change from the last price of $33.51.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Monopar Therapeutics stock Price Target by analysts
Full breakdown of analysts given Monopar Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Justin Walsh UBS | 0% 0/1 | 10 months ago | $37 10.41% upside | $19.01 | StreetInsider | Previous targets (0) |
Sean Lee H.C. Wainwright | 0% 0/1 | 10 months ago | $22 -34.34% downside | $15.81 | StreetInsider | Previous targets (0) |
Monopar Therapeutics Financial Estimates
Monopar Therapeutics Revenue Estimates
Monopar Therapeutics EBITDA Estimates
Monopar Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $2.14M Low: $2.14M High: $2.14M avg. 0% | Avg: $17.03M Low: $17.03M High: $17.03M avg. 694.30% |
Net Income
% change YoY
| $-9.07M N/A | $-10.49M -15.58% | $-8.40M 19.93% | Avg: $-9.23M Low: $-4.83M High: $-3.87M avg. -9.91% | Avg: $-8.89M Low: $-5.25M High: $-2.35M avg. 3.65% | Avg: $-2.90M Low: $-2.90M High: $-2.90M avg. 67.37% | Avg: $276.47K Low: $276.47K High: $276.47K avg. 109.52% |
EBITDA
% change YoY
| $-9.12M N/A | $-10.53M -15.44% | $429.03K 104.07% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$0.73 N/A | -$0.83 -13.69% | -$0.58 30.12% | Avg: -$0.32 Low: -$0.35 High: -$0.28 avg. 45.68% | Avg: -$0.28 Low: -$0.38 High: -$0.17 avg. 12.69% | Avg: -$0.21 Low: -$0.21 High: -$0.21 avg. 23.63% | Avg: $0.02 Low: $0.02 High: $0.02 avg. 109.52% |
Operating Expenses
% change YoY
| $9.12M N/A | $10.53M 15.44% | $8.83M -16.18% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is Monopar Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 42.65% in 2025-2028.
We have gathered data from 1 analysts. Their low estimate is -4.83M, average is -9.23M and high is -3.87M.
What is Monopar Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 173.57% in 2025-2028.
We have gathered data from 3 analysts. Their low revenue estimate is N/A, average is N/A and high is N/A.
What is Monopar Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 47.88% in 2025-2028.
We have gathered data from 1 analysts. Their low earnings per share estimate is -$0.35, average is -$0.32 and high is $-0.28.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Monopar Therapeutics stock. The most successful analyst is Justin Walsh.